Clinical effect of pharmaceutical products using communication tool integrated with compound of several pharmaceutical products

Abstract

A combination of N>1 substances with pharmaceutical activity against at least one medical condition for treating the medical condition with a program including instructions causing a computer to perform a method including: providing a patient with a set of questions adapted to the combination according to a question schedule; providing a patient with N sets of questions according to N question schedules, wherein each set of questions is adapted to one substance; collecting answers to the sets of questions from the patient; subjecting the answers to the set of questions adapted to the combination to a set of functions, thereby generating a first patient feedback; subjecting the answers to the sets of questions each adapted for one substance, to N sets of functions, thereby generating a second patient specific feedback; and providing the first and second specific feedbacks to the patient.

1 . Combination of N substances, wherein N>1, with pharmaceutical activity against at least one medical condition for use in a treatment of said at least one medical condition in combination with a computer program product ( 110 ) comprising instructions causing a computer to perform a method comprising the steps
 providing a patient ( 102 ) with a set of questions ( 107 ) according to a question schedule, wherein said set of questions is adapted to said combination of substances;   providing a patient with N sets of questions ( 106   1 , - 106   N ) according to N question schedules, wherein each set of questions is adapted to one of the substances in said combination;   collecting answers to said sets of questions from said patient;   subjecting the answers to said set of questions ( 107 ) adapted to said combination of substances to a set of functions ( 109 ), thereby generating a first patient specific feedback information;   subjecting the answers to said sets of questions ( 106   1 , - 106   N ), each adapted for one of the substances in said combination, to N sets of functions ( 108   1 , - 108   N ), thereby generating a second patient specific feedback information;   providing said first and second patient specific feedback to the patient; and   optionally extracting information from said answers and providing said information to a database adapted for collecting information during clinical use of said combination of substances.   
     
     
         2 . Combination of substances according to  claim 1 , wherein the computer program product ( 110 ) comprises instructions causing a computer to perform a method comprising the steps
 providing at least one further respondent ( 102 ′) in addition to said patient ( 102 ) with a second set of questions ( 106 ′) according to a second question schedule, wherein said second set of questions ( 106 ′) is adapted to the combination of substances and/or to at least one of the substances in said combination;   collecting answers to said questions ( 106 ′) from said further respondent ( 102 ′);   subjecting said answers from said further respondent ( 102 ′) to a second set of functions ( 1068 ) adapted to the second set of questions ( 108 ′) and the combination of substances and/or to at least one of the substances in said combination thereby generating patient-specific feedback information;   providing said feedback information to the patient ( 102 ) and, optionally, to the further respondent ( 102 ′); and   optionally extracting information from said answers from said further respondent ( 102 ′) and providing said information to a database adapted for collecting information during clinical use of said combination of substances.   
     
     
         3 . Combination of substances according to  claim 1 , wherein the computer program product comprising instructions causes a computer to perform a method comprising the steps
 a) providing a patient and optionally a further respondent with sets of questions according to a question schedule, wherein said sets of questions are adapted to the combination of substances and/or to at least one of the substances in said combination;   b) collecting answers to said questions from said patient and optionally said further respondent;   c) subjecting said answers to a set of functions adapted for the sets of questions and the pharmaceutical product thereby generating patient-specific feedback information;   d) providing said feedback information to the patient and optionally to the further respondent;   e) extracting information from said answers and providing said information to a database adapted for storing information collected during clinical use of said combination of substances;   f) providing information stored in said database to a reviser subjecting the sets of questions and/or the sets of functions to a revision based on said information stored in said database;   g) obtaining a revised set of questions and/or a revised set of functions from said reviser; and   h) repeating steps a)-g).   
     
     
         4 . Combination of substance according to  claim 1 , wherein said database is adapted for storing information collected from more than one patient, preferably at least 50%, such as at least 75% or substantially 100% of patients, clinically using said combination of substances in combination with said computer program product. 
     
     
         5 . Combination of substances according to  claim 3 , wherein said revision is based on information collected from said patient and/or other patients clinically using said combination of substances in combination with said computer program product. 
     
     
         6 . Combination of substances according to  claim 1 , wherein said revision is based on information obtained during clinical trials of the substance and/or commercial use of the substance. 
     
     
         7 . Combination of substances according to  claim 1 , wherein said database is adapted to store information comprising one or more of: patient identifier, respondent identifier, individual caregiver identifier, organizational caregiver identifier, substance identifier, substance combination identifier, respondent answers, type and date of occurrence of adverse events, type and degree of adverse effects of one or more substance or substance combination, probability of an adverse event, probability of an adverse effect, patient health status, patient history, patient family history, patient genetic information, prescribed dosage or administration regimen, drug-drug interactions, life-style factors. 
     
     
         8 . A combination of substances according to  claim 1 , wherein the clinical relevance of the combination of said set of questions and said set of functions has been validated in clinical trials. 
     
     
         9 . A combination of substances according to  claim 1 , wherein said set of questions and said set of functions are related to patient compliance to a preferred or prescribed dosage and/or administration regimen of said combination of substances. 
     
     
         10 . A combination of substances according to  claim 1 , wherein said set of questions and said set of functions are related to an indication of possible occurrence or development of an adverse event and/or side effect. 
     
     
         11 . A combination of substances according to  claim 1 , wherein said set of questions and said set of functions are related to the patient's quality of life. 
     
     
         12 . A combination of substances according to  claim 1 , wherein at least a subset of the set of questions is related to the actual administration; actual dosage; perceived and/or measured therapeutic effects; test results and/or perceived quality of life. 
     
     
         13 . A combination of substances according to  claim 1 , wherein the method further comprises subjecting said answers to a set of functions specific for the set of questions and the pharmaceutical product thereby generating an updated question schedule, wherein said set of functions optionally use Computer Adaptive Testing and/or Item Response Theory. 
     
     
         14 . A combination of substances according to  claim 1 , wherein said set of functions include functions selected from the group consisting of: calculations of target parameters and trend lines; prediction of development of a condition; rules and thresholds for defining when to give notifications. 
     
     
         15 . A combination of substances according to  claim 1 , wherein said computer program product comprises instructions causing a computer to provide feedback selected from graphs, diagrams, graphical illustrations and text messages. 
     
     
         16 . A combination of substances according to  claim 1 , wherein said method provides feedback only to the patient, or to the patient and to other individuals. 
     
     
         17 . A combination of substances according to  claim 1 , wherein said computer program product is provided on a physical medium or by means or instructions for accessing and installing the computer program product on a computer. 
     
     
         18 . A kit of parts comprising a combination of substances and a computer program product according to  claim 17 , wherein said computer program product is provided by means or instructions for accessing and installing the computer program product on a computer and said kit further comprises an identifier unique to the kit. 
     
     
         19 . A combination of substances according to  claim 1 , wherein the substances in said combination of substances are selected from the group consisting of Aripiprazol (Abilify), Rimonabant (Acomplia), Pioglitazon (Actos), glucoseamine (Glucosine), Octocog alfa (Advate, Advair), Flutikason in combination with Salmeterol (Seretide), zolpidem (Ambien, Stilnox), Insulin glulisin (Apidra), Donepezil (Aricept), irbesartan (Avapro, Aprovel), rosiglitazone (Avandia), metformin in combination with rosiglitazone (Avandamet), glimepiride in combination with rosiglitazone (Avandaryl), bevacizumab (Avastin), Interferon beta (Avonex), Darbepoetin alfa (Aranesp), anastrozole (Arimidex), Kandesartan (Atacand), olmesartan (Benicar, Olmetec), Interferon beta-1b (Betaseron), Interferon beta (Betaferon), exenatide (Byetta), Bikalutamid (Casodex), Celecoxib (Celebrex, Celebra), Escitalopram (Cipralex/Lexapro), duloxetine (Cymbalta), Vareniklin (Champix), Glatiramer (Copaxone), Carvedilol (Coreg), Losartan (Cozaar), Rosuvastatin (Crestor), Ramipril (Tritace), Valsartan (Diovan), Venlafaxin (Efexor), oxaliplatin (Eloxatin), Etanercept (Enbrel), raloxifene (Evista), ezetimibe (Ezetrol, Zetia), Tamsulosin (Flomax, Flomaxtra, Urimax), fluticasone (Flovent, Flixotide), Alendronic acid (Fosamax), Gemcitabine (Gemzar), imatinib mesylate (Gleevec, Glivec), Trastuzumab (Herceptin), insulin lispro (Humalog), Adalimumab (Humira), Lopinavir/ritonavir (Kaletra), Sumatriptan (Imitrex, Imigran), Sitagliptin (Januvia), insulin glargin (Lantus), Fenofibrate (Lipanthyl, TriCor), atorvastatin (Lipitor), Insulin Detemir (Levemir), amlodipine and benazepril (Lotrel), Leuprorelin, (Lupron, Leuplin), pregabalin (Lyrica), rituximab (Mabthera, Rituxan), Telmisartan (Micardis), Esomeprazole (Nexium), amlodipine (Norvasc), insulin aspart (NovoLog, NovoMix, NovoRapid), repaglinid (NovoNorm), Rabeprazole (Pariet), paroxetine (Paxil, Seroxat), Pantoprazole (Protonix, Pantozol, Pantoloc), Clopidogrel (Plavix), pravastatin (Pravachol), Epoetin Alfa (Procrit, Eprex), takrolimus (Protopic), budesonid (Pulmicort), interferon beta-1a (Rebif), sibutramin (Reductil), Infliximab (Remicade), Risperidon (Risperdal), Metoprolol (Seloken, Toprol), quetiapine (Seroquel), Tiotropium (Spiriva), budesonide and formoterol (Symbicort), Montelukast (Singulair), Docetaxel (Taxotere), Topiramat (Topamax), Emtricitabin and Tenofovirdisoproxil (Truvada), ezetimibe and simvastatin (Vytorin), bupropion (Wellbutrin), Betametason in combination with Kalcipotriol (Xamiol) calcipotriene (Taclonex), simvastatin (Zocor), Sertralin (Zoloft), zoledronic acid (Zometa), Olanzapin (Zyprexa), cetirizine (Zyrtec), ticagrelor (Brilique). 
     
     
         20 . The computer program product of  claim 1 . 
     
     
         21 . The method of  claim 1 .